propentofylline has been researched along with Nerve Pain in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The markedly delayed efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug failures after shorter dosing regimens." | 5.40 | Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain. ( Ellis, A; Falci, S; Favret, J; Johnson, KW; Maier, SF; Rice, KC; Watkins, LR; Wieseler, J, 2014) |
| " Among the many therapeutic agents that have been tested for anti-allodynia through immune modulation is the atypical methylxanthine propentofylline." | 3.81 | Modulation of spinal glial reactivity by intrathecal PPF is not sufficient to inhibit mechanical allodynia induced by nerve crush. ( Damblon, J; De Kock, M; Des Rieux, A; Deumens, R; Dimiziani, A; Gallo, A; Hermans, E; Michot, B, 2015) |
| "Neuropathic pain is one of the most important types of chronic pain." | 1.51 | The NOD2 signaling in peripheral macrophages contributes to neuropathic pain development. ( Alves-Filho, JC; Cecilio, NT; Cunha, FQ; Cunha, TM; Davoli-Ferreira, M; Ferreira, DW; Fonseca, MM; Guimaraes, RM; Kusuda, R; Lopes, AH; Nachbur, U; Santa-Cecília, FV; Souza, GR; Teixeira, MM; Zamboni, DS, 2019) |
| "Our findings showed that the mechanical allodynia, and synaptically-evoked firing were caused LTP in the Aδ-fiber, C-fiber and lesser in the Aβ-fiber after high frequency stimulation." | 1.51 | Role of spinal glial cells in excitability of wide dynamic range neurons and the development of neuropathic pain with the L5 spinal nerve transection in the rats: Behavioral and electrophysiological study. ( Haghparast, A; Manaheji, H; Rezaee, L, 2019) |
| "Ibudilast is a phosphodiesterase inhibitor with anti-inflammatory activity, but its effect on activated microglia in chronic neuropathic pain is poorly understood." | 1.48 | Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline. ( Asaki, T; Fujita, M; Hasegawa, M; Omachi, S; Rokushima, M; Sakaguchi, G; Shinohara, S; Tamano, R; Yogo, E; Yoneda, S, 2018) |
| " The markedly delayed efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug failures after shorter dosing regimens." | 1.40 | Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain. ( Ellis, A; Falci, S; Favret, J; Johnson, KW; Maier, SF; Rice, KC; Watkins, LR; Wieseler, J, 2014) |
| "Rats underwent SNL surgery to induce neuropathic pain." | 1.39 | Tramadol and propentofylline coadministration exerted synergistic effects on rat spinal nerve ligation-induced neuropathic pain. ( Liu, R; Mei, XP; Wang, H; Wang, W; Wu, D; Xie, C; Xu, LX; Zhang, H; Zhang, J, 2013) |
| "Propentofylline treatment on days 14-21 or 60-67 did not reverse existing allodynia." | 1.36 | Activation of astrocytes in the spinal cord contributes to the development of bilateral allodynia after peripheral nerve injury in rats. ( Kimura, M; Obata, H; Saito, S; Sakurazawa, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, M | 1 |
| Tamano, R | 1 |
| Yoneda, S | 1 |
| Omachi, S | 1 |
| Yogo, E | 1 |
| Rokushima, M | 1 |
| Shinohara, S | 1 |
| Sakaguchi, G | 1 |
| Hasegawa, M | 1 |
| Asaki, T | 1 |
| Santa-Cecília, FV | 1 |
| Ferreira, DW | 1 |
| Guimaraes, RM | 1 |
| Cecilio, NT | 1 |
| Fonseca, MM | 1 |
| Lopes, AH | 1 |
| Davoli-Ferreira, M | 1 |
| Kusuda, R | 1 |
| Souza, GR | 1 |
| Nachbur, U | 1 |
| Alves-Filho, JC | 1 |
| Teixeira, MM | 1 |
| Zamboni, DS | 1 |
| Cunha, FQ | 1 |
| Cunha, TM | 1 |
| Rezaee, L | 1 |
| Manaheji, H | 1 |
| Haghparast, A | 1 |
| Wu, F | 1 |
| Miao, X | 1 |
| Chen, J | 1 |
| Liu, Z | 1 |
| Tao, Y | 1 |
| Yu, W | 1 |
| Sun, Y | 1 |
| Zhang, J | 1 |
| Wu, D | 1 |
| Xie, C | 1 |
| Wang, H | 1 |
| Wang, W | 1 |
| Zhang, H | 1 |
| Liu, R | 1 |
| Xu, LX | 1 |
| Mei, XP | 1 |
| Ellis, A | 1 |
| Wieseler, J | 1 |
| Favret, J | 1 |
| Johnson, KW | 1 |
| Rice, KC | 1 |
| Maier, SF | 1 |
| Falci, S | 1 |
| Watkins, LR | 1 |
| Gallo, A | 1 |
| Dimiziani, A | 1 |
| Damblon, J | 1 |
| Michot, B | 1 |
| Des Rieux, A | 1 |
| De Kock, M | 1 |
| Hermans, E | 1 |
| Deumens, R | 1 |
| Obata, H | 1 |
| Sakurazawa, S | 1 |
| Kimura, M | 1 |
| Saito, S | 1 |
| Constandil, L | 1 |
| Goich, M | 1 |
| Hernández, A | 1 |
| Bourgeais, L | 1 |
| Cazorla, M | 1 |
| Hamon, M | 1 |
| Villanueva, L | 1 |
| Pelissier, T | 1 |
| Garry, EM | 1 |
| Delaney, A | 1 |
| Blackburn-Munro, G | 1 |
| Dickinson, T | 1 |
| Moss, A | 1 |
| Nakalembe, I | 1 |
| Robertson, DC | 1 |
| Rosie, R | 1 |
| Robberecht, P | 1 |
| Mitchell, R | 1 |
| Fleetwood-Walker, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Full-Factorial, Parallel-Group Study Evaluating Safety and Efficacy of Naltrexone-Acetaminophen Combination in Acute Migraine Treatment in Adults, With Exploratory Focus on Co-Occurring[NCT05685225] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 other studies available for propentofylline and Nerve Pain
| Article | Year |
|---|---|
Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Hyperalgesia; Injections, Spin | 2018 |
The NOD2 signaling in peripheral macrophages contributes to neuropathic pain development.
Topics: Animals; Bone Marrow Transplantation; Carrageenan; Disease Models, Animal; Inflammation; Interleukin | 2019 |
Role of spinal glial cells in excitability of wide dynamic range neurons and the development of neuropathic pain with the L5 spinal nerve transection in the rats: Behavioral and electrophysiological study.
Topics: Animals; Behavior, Animal; Electrophysiological Phenomena; Hyperalgesia; Ligation; Long-Term Potenti | 2019 |
Inhibition of GAP-43 by propentofylline in a rat model of neuropathic pain.
Topics: Animals; Astrocytes; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; F | 2013 |
Tramadol and propentofylline coadministration exerted synergistic effects on rat spinal nerve ligation-induced neuropathic pain.
Topics: Analgesics, Opioid; Animals; Drug Combinations; Drug Synergism; Hyperalgesia; Injections, Spinal; In | 2013 |
Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain.
Topics: Animals; Disease Models, Animal; Hyperalgesia; Male; Naltrexone; Narcotic Antagonists; Neuralgia; Ne | 2014 |
Modulation of spinal glial reactivity by intrathecal PPF is not sufficient to inhibit mechanical allodynia induced by nerve crush.
Topics: Animals; Calcium-Binding Proteins; Female; Glial Fibrillary Acidic Protein; Hyperalgesia; Injections | 2015 |
Activation of astrocytes in the spinal cord contributes to the development of bilateral allodynia after peripheral nerve injury in rats.
Topics: Animals; Astrocytes; Dose-Response Relationship, Drug; Hyperalgesia; Injections, Spinal; Lumbar Vert | 2010 |
Cyclotraxin-B, a new TrkB antagonist, and glial blockade by propentofylline, equally prevent and reverse cold allodynia induced by BDNF or partial infraorbital nerve constriction in mice.
Topics: Analgesics; Animals; Brain-Derived Neurotrophic Factor; Central Nervous System Sensitization; Cold T | 2012 |
Activation of p38 and p42/44 MAP kinase in neuropathic pain: involvement of VPAC2 and NK2 receptors and mediation by spinal glia.
Topics: Animals; Disease Models, Animal; Enzyme Activation; Enzyme Inhibitors; Inflammation Mediators; Male; | 2005 |